•
China’s Shanghai SIMR Biotechnology Co., Ltd has reportedly raised RMB 150 million (USD 20.7 million) in a Series C1 financing round, alongside “tens of millions” in bank loans. Investors included Guanzi Private Fund Management, Tian Rui Feng Nian, and Yixing Huarui. The proceeds will be used to support pre-clinical development,…